UBS kept its EUR 300 target for Sartorius stock before results

Published on 10/21/2026 at 10:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Third-quarter results are due October 22, 2026. Sartorius stock costs EUR 265.25 on October 21, 2026 versus its EUR 264.70 Xetra close.

Analyst view and trading context

UBS retained its Buy rating and EUR 300.00 target on October 15, 2026.
Fiscal 2025 sales reached EUR 3.5 billion, while the underlying EBITDA margin was 29.7 percent.
Sartorius stock trades at EUR 265.25 at 10:48 a.m. CEST at Lang & Schwarz on October 21, 2026, 0.21 percent above the Xetra close of October 20, 2026.

Fotorealistische Bioreaktor-Anlage in Reinraumhalle mit Edelstahltanks und Technikern — Sartorius AG (Vz.) DE0006292006 zeigt fotorealistisch eine sterile Bioreaktor-Anlage mit Technikern in weißer Reinraum-Schutzkleidung, Illustration mit AI erstellt.

Sartorius (ISIN DE0007165631) was trading at EUR 265.25 at Lang & Schwarz on October 21, 2026, at 10:48 a.m. CEST, up EUR 0.55, or 0.21 percent, versus the Xetra close of October 20, 2026, at EUR 264.70. According to FinanzNachrichten on October 15, 2026, UBS had retained its Buy rating and EUR 300.00 target before Sartorius results expected on October 22, 2026.

Target leaves a 13.10 percent gap

The UBS target lies 13.10 percent above the EUR 265.25 reference price. The rating came with a qualification: analyst Matthew Weston said tariff factors would need to be considered when assessing the company's underlying growth path, according to FinanzNachrichten.

Three target moves set the timeline

On September 30, 2026, Goldman Sachs raised its Sartorius target from EUR 228.00 to EUR 244.00 while keeping a Neutral rating, as FinanzNachrichten reported. On October 12, 2026, JPMorgan kept its Overweight rating and EUR 295.00 target, according to FinanzNachrichten. UBS followed on October 15, 2026, with the EUR 300.00 target and Buy rating.

What arrives on October 22?

The next two scheduled items are both dated October 22, 2026: Sartorius is expected to publish its third-quarter results, while the company has scheduled its 9M 2026 results conference call for 1 p.m. CEST, according to FinanzNachrichten and Sartorius. The figures will test whether the recovery in bioprocessing is translating into broader operating momentum.

Historical context remains important. Sartorius reported fiscal 2025 sales of EUR 3.5 billion, up 7.6 percent from the prior year, and an underlying EBITDA margin of 29.7 percent, according to its investor relations page. Its fiscal 2026 guidance calls for sales growth between 5 and 9 percent in constant currencies and an underlying EBITDA margin slightly above 30 percent.

Stock stays below its yearly high

The market capitalization was EUR 16.1 billion as of October 21, 2026. The 52-week range was EUR 175.95 to EUR 271.90, placing the Lang & Schwarz price 2.45 percent below the high.

Sartorius was trading at EUR 265.25 at Lang & Schwarz on October 21, 2026, at 10:48 a.m. CEST, 0.21 percent above the Xetra close of October 20, 2026, at EUR 264.70. The further course of trading is shown by the continuously updated real-time quote of Sartorius stock.